| Lynn Ann Litwinczyk, SLP | |
|
124 Hopmeadow Rd, Bristol, CT 06010-2209 | |
| (860) 582-0546 | |
| Not Available |
| Full Name | Lynn Ann Litwinczyk |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 124 Hopmeadow Rd, Bristol, Connecticut |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1770828790 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 002474 (Connecticut) | Primary |
| Provider Name | Fox Rehab Slp Ct Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1588918569 PECOS PAC ID: 0446499891 Enrollment ID: O20130617000352 |
News Archive
YM BioSciences Inc., announced that the FDA has advised the Company that it may now enroll patients at US clinical sites into two ongoing randomized, double-blind Phase II trials of its lead product, nimotuzumab. One of the two trials is in non-small-cell lung cancer (NSCLC) patients who are ineligible for curative treatment and being treated palliatively and the other in patients with brain metastases from NSCLC. Current NSCLC palliative treatment and treatment for brain metastases is radiation alone.
Sanofi-aventis U.S. and Bristol-Myers Squibb Company today announced revisions to the U.S. prescribing information for PLAVIX® (clopidogrel bisulfate), which include a boxed warning. The boxed warning concerns the diminished effectiveness of PLAVIX in patients who have a genetic variation leading to reduced formation of the active metabolite.
New research shows that current approaches to genome analysis systematically miss detecting a certain type of complex mutation in cancer patients' tumors. Further, a significant percentage of these complex mutations are found in well-known cancer genes that could be targeted by existing drugs, potentially expanding the number of cancer patients who may benefit.
Boston Scientific Corporation today announced the start of patient enrollment in the EVIDENCE Clinical Trial, which compares the therapeutic effectiveness and cost effectiveness of spinal cord stimulation (SCS) therapy to spine reoperation in patients with failed back surgery syndrome (FBSS). The first patient was enrolled by Joseph Buwembo, M.D. and Krishna Kumar, M.D., F.R.C.S.C., at Regina General Hospital in Regina, Saskatchewan, Canada.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lynn Ann Litwinczyk, SLP 124 Hopmeadow Rd, Bristol, CT 06010-2209 Ph: (860) 582-0546 | Lynn Ann Litwinczyk, SLP 124 Hopmeadow Rd, Bristol, CT 06010-2209 Ph: (860) 582-0546 |
News Archive
YM BioSciences Inc., announced that the FDA has advised the Company that it may now enroll patients at US clinical sites into two ongoing randomized, double-blind Phase II trials of its lead product, nimotuzumab. One of the two trials is in non-small-cell lung cancer (NSCLC) patients who are ineligible for curative treatment and being treated palliatively and the other in patients with brain metastases from NSCLC. Current NSCLC palliative treatment and treatment for brain metastases is radiation alone.
Sanofi-aventis U.S. and Bristol-Myers Squibb Company today announced revisions to the U.S. prescribing information for PLAVIX® (clopidogrel bisulfate), which include a boxed warning. The boxed warning concerns the diminished effectiveness of PLAVIX in patients who have a genetic variation leading to reduced formation of the active metabolite.
New research shows that current approaches to genome analysis systematically miss detecting a certain type of complex mutation in cancer patients' tumors. Further, a significant percentage of these complex mutations are found in well-known cancer genes that could be targeted by existing drugs, potentially expanding the number of cancer patients who may benefit.
Boston Scientific Corporation today announced the start of patient enrollment in the EVIDENCE Clinical Trial, which compares the therapeutic effectiveness and cost effectiveness of spinal cord stimulation (SCS) therapy to spine reoperation in patients with failed back surgery syndrome (FBSS). The first patient was enrolled by Joseph Buwembo, M.D. and Krishna Kumar, M.D., F.R.C.S.C., at Regina General Hospital in Regina, Saskatchewan, Canada.
› Verified 7 days ago
Christine Xanthoudakis, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 400 N Main St, Bristol, CT 06010 Phone: 860-584-3400 | |
Katherine Tilley Sullivan, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 440 N Main St, Bristol, CT 06010 Phone: 860-893-1977 | |
Tara Turken, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1660 Stafford Ave, Bristol, CT 06010 Phone: 860-583-8483 | |
Miss Sara Marie Tye, M.S., CCC-SLP Speech-Language Pathologist Medicare: Accepting Medicare Assignments Practice Location: 145 Fox Den Rd, Bristol, CT 06010 Phone: 860-716-0715 | |
Learn Play Grow Speech Therapy Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 143 Sherwood Rd, Bristol, CT 06010 Phone: 860-999-1487 | |
Septimiu Cozmuta, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 23 Fair St, Bristol, CT 06010 Phone: 860-589-2923 |